As it has been previously shown that the BRAF V600E mutation conveys sensitivity of melanoma cells to BRAF [34], [35], [36] and MEK [37] inhibitors and the phenothiazine compounds [38], we next addressed whether the presence of a BRAF or NRAS mutation conferred sensitivity to dinaciclib. Here, MAP2K7 is linked to melanoma.